Clinical trials: Peripheral Artery Diseases
Coronary Artery Disease, Pain
Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy
This study was to determine whether ranolazine was effective in the treatment of neuropathic pain in patients with coronary artery disease.
- Conditions
- Coronary Artery Disease, Pain, Peripheral Nervous System Diseases, Polyneuropathy
- Trial name
- NCT00832572
- Testing
- Ranolazine
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Gilead Sciences
Diabetic Foot, Peripheral Arterial Disease
Hemodynamic Effects of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease
Study PDA-002-DFU-003 is a Phase 2, multicenter, randomized, double blind, placebo-controlled, dose range finding study in subjects who have diabetic foot ulcer (DFU) with peripheral arterial disease (PAD).
- Trial name
- NCT02460081
- Testing
- PDA-002
- Where
- United States
- Sponsor
- Celularity Incorporated
Coronary Artery Disease (CAD), Peripheral Artery Disease (PAD)
A Study to Assess the Engagement and Usefulness of Care4Today Digital Platform for Disease Management in Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD) Population
The purpose of this study is to assess the engagement and usefulness of Care4Today® Connect CAD-PAD digital platform in participants with coronary artery disease or peripheral artery disease (CAD or PAD).
- Trial name
- IPACE-CVD (NCT06052319)
- Testing
- Care4Today® Connect CAD-PAD Mobile Application
- Where
- 6 sites in United States
- Volunteers
- 277 people
- Sponsor
- Janssen Scientific Affairs, LLC
Critical Limb Ischemia
Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Critical Limb Ischemia
This is a double-blind, placebo controlled study designed to evaluate the safety and efficacy of JVS-100 given to adult subjects with critical limb ischemia (CLI).
- Trial name
- NCT01410331
- Where
- 7 sites in United States, India
- Volunteers
- 48 people
- Sponsor
- Juventas Therapeutics, Inc.
Peripheral Artery Disease
A Study Related to the VOYAGER PAD Trial to Learn More About the Target Population for Xarelto in French Patients
This is a study to learn more about French patients who have peripheral artery disease (PAD) and who have had a revascularization procedure.
- Trial name
- PADELTO (NCT04824729)
- Testing
- Lower limb revascularization
- Where
- France
- Volunteers
- 227,613 people
- Sponsor
- Bayer
Critical Limb Ischemia
Safety and Preliminary Efficacy of Allogeneic Endothelial Progenitor Cells (EPCs) in Patients With Critical Limb Ischemia
The purpose of this study is to determine if allogeneic Endothelial Progenitor Cells (EPCs) intravenous infusion to a subject with leg ulcer and/or gangrene due to poor blood flow will be safe and if it will relieve leg pain…
- Trial name
- NCT06359912
- Testing
- EPCs, Clinical standard treatment (CST)
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Allife Medical Science and Technology Co., Ltd.
Peripheral Arterial Hemorrhage, Trauma
Onyx™ Liquid Embolic IDE Clinical Study
The purpose of this study is to evaluate the safety and effectiveness of Onyx™ LES in the treatment of subjects with active arterial bleeding in the peripheral vasculature outside of the heart and brain.
- Conditions
- Peripheral Arterial Hemorrhage, Trauma, GI Bleed, Ulcer
- Trial name
- NCT06742801
- Testing
- Onyx™ Liquid Embolic System
- Where
- 20 sites in United States
- Volunteers
- 119 people
- Sponsor
- Medtronic Endovascular
Peripheral Vascular Diseases, Hemostasis
Trial to Evaluate the Hemostatic Effect of Lyostypt® Versus Surgicel® in Arterial Bypass Anastomosis
The purpose of this trial is to demonstrate that the bleeding time of suture holes after construction of arterial bypass anastomosis is shorter after treatment with Lyostypt® than with Surgicel®
- Trial name
- COBBANA (NCT00837954)
- Testing
- Lyostypt® AND Surgicel®, Lyostypt®, Surgicel®
- Where
- Germany
- Volunteers
- 32 people
- Sponsor
- Aesculap AG
Cancer
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
RATIONALE: Hepatic arterial infusion uses a catheter to deliver anticancer substances directly into the liver. Drugs used in chemotherapy, such as melphalan, work in different ways to stop tumor cells from dividing so they stop…
- Trial name
- NCT00096083
- Testing
- isolated perfusion, melphalan
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Delcath Systems Inc.
Peripheral Vascular Diseases
Efficacy and Safety of XRP0038/NV1FGF in Critical Limb Ischemia Patients With Skin Lesions
Primary objective is to demonstrate the superiority of riferminogene pecaplasmid (XRP0038/NV1FGF) over placebo in the prevention of major amputation above the ankle of the treated leg or of death from any cause, whichever comes…
- Trial name
- TAMARIS (NCT00566657)
- Testing
- riferminogene pecaplasmid
- Where
- 32 sites in United States, Argentina and 30 more
- Volunteers
- 525 people
- Sponsor
- Sanofi
Peripheral Arterial Disease
Observational Study to Assess Transradial Access for Treatment in the Lower Extremities.
This study is designed to collect data on the complication rates and procedural success of using a transradial access approach to treat peripheral lesions in the lower extremities of a real world population.
- Trial name
- R2P Registry (NCT04371861)
- Testing
- Peripheral Artery Treatment
- Where
- 8 sites in United States
- Volunteers
- 120 people
- Sponsor
- Terumo Medical Corporation
Peripheral Vascular Disease
Evaluation of Fibrin Sealant 2 in Vascular Surgical Procedures
A comparison of a fibrin sealant versus manual compression in stopping surgical bleeding during vascular procedures.
- Trial name
- NCT00154141
- Testing
- Fibrin sealant (FS2)
- Where
- 17 sites in United States, United Kingdom
- Volunteers
- 150 people
- Sponsor
- Ethicon, Inc.
Peripheral Arterial Disease, Acute Limb Ischemia
Pounce™ Thrombectomy System Retrospective Registry
The PROWL registry is an open-label retrospective, multi-center, US study of the Surmodics™ Pounce™ Thrombectomy System for the non-surgical removal of emboli and thrombi in the peripheral arterial vasculature.
- Trial name
- PROWL (NCT05868161)
- Testing
- Pounce Thrombectomy System
- Where
- 9 sites in United States
- Volunteers
- 500 people
- Sponsor
- SurModics, Inc.
Peripheral Arterial Disease
Use of Interlocking Detachable Coils System in Embolization of Peripheral Arterial Embolization
The purpose of this study is to evaluate the safety and efficacy of interlocking detachable coils system in the treatment of Chinese patients with embolization of peripheral arterial in comparison with Interlock Fibered IDC…
- Trial name
- NCT05391399
- Testing
- Interlocking detachable coils system, Interlock Fibered IDC Occlusion System
- Where
- China
- Volunteers
- 121 people
- Sponsor
- Shanghai Shenqi Medical Technology Co., Ltd
Critical Limb Ischemia, Buerger's Disease
Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Buerger's Disease
The goal of this observational, practice-based feasibility study is to observe the efficacy and safety of intramuscular administration of Stempeucel® in Malaysian patients with critical limb ischemia (CLI) due to Buerger's…
- Trial name
- NCT05854615
- Testing
- Adult human bone marrow derived, cultured, pooled, allogeneic mesenchymal stromal cells
- Where
- Malaysia
- Volunteers
- 3 people
- Sponsor
- Cell Biopeutics Resources Sdn Bhd
Periferal Arterial Occlusive Disease, PAOD
Effect on Blood Flow Using the FlowOx™ Device in Patients With Reduced Peripheral Circulation in the Lower Leg
A study to assess the effect of negative pulsating pressure therapy on patients with impaired blood flow to the leg caused by arterial disease, to see if the FlowOx device will increase the blood flow to the leg in these patients.
- Trial name
- NCT01893840
- Testing
- FlowOx
- Where
- Norway
- Volunteers
- 20 people
- Sponsor
- Otivio AS
Intermittent Claudication, Peripheral Vascular Disease
Trial of VLTS-589 in Subjects With Intermittent Claudication
The purpose of this study is to evaluate the safety and tolerability of VLTS-589 compared with placebo, administered bilaterally to the lower extremities, in subjects with intermittent claudication and to determine the effect of…
- Trial name
- NCT00068133
- Testing
- Plasmid based Gene Transfer product-VLTS-589
- Where
- 20 sites in United States
- Volunteers
- 100 people
- Sponsor
- Valentis
Peripheral Arterial Disease
SDF1 Plasmid Treatment for Patients With Peripheral Artery Disease
To investigate the efficacy of the administration of JVS-100 delivered via direct intramuscular injections on a 3 month and 6 month composite endpoint of wound progression, healing and limb loss in patients with severe peripheral…
- Trial name
- STOP-PAD (NCT02544204)
- Testing
- JVS-100
- Where
- 24 sites in United States
- Volunteers
- 120 people
- Sponsor
- Juventas Therapeutics, Inc.
Peripheral Arterial Disease
ModificatiOn and Treatment of stenoseD Calcified inFrainguinal Lesions With Laser atherectomY in a Pilot Study
The MODIFY Pilot clinical study in Europe looks to evaluate acute and procedural outcomes using a new calcium atherectomy and modification solution in patients with balloon resistant calcified lesions in infrainguinal disease.
- Trial name
- MODIFY (NCT03268018)
- Testing
- Laser induced pressure wave calcium modification
- Where
- 2 sites in Belgium
- Volunteers
- 8 people
- Sponsor
- Spectranetics Corporation
Critical Limb Ischemia, Peripheral Arterial Disease
ALD-301 for Critical Limb Ischemia, Randomized Trial
This study will treat patients with such severe lower leg ischemia or vascular compromise that they have pain at rest. The goal is to compare treatment of the patient's painful disorder by injecting cells into the calf of the leg…
- Conditions
- Critical Limb Ischemia, Peripheral Arterial Disease, Peripheral Vascular Disease
- Trial name
- CLI-001 (NCT00392509)
- Testing
- ALDH-br bone marrow cells vs. mononuclear bone marrow cells
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- Aldagen